These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 10577301

  • 1. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy.
    Pincus T, O'Dell JR, Kremer JM.
    Ann Intern Med; 1999 Nov 16; 131(10):768-74. PubMed ID: 10577301
    [Abstract] [Full Text] [Related]

  • 2. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
    Kremer JM.
    Ann Intern Med; 2001 Apr 17; 134(8):695-706. PubMed ID: 11304108
    [Abstract] [Full Text] [Related]

  • 3. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
    Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blåfield H, Puolakka K, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2004 Jul 17; 50(7):2072-81. PubMed ID: 15248204
    [Abstract] [Full Text] [Related]

  • 4. [Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
    Suzuki Y, Wakabayashi T, Saito E, Suwa A.
    Clin Calcium; 2007 Apr 17; 17(4):546-52. PubMed ID: 17404484
    [Abstract] [Full Text] [Related]

  • 5. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C.
    Arthritis Res Ther; 2018 Jan 02; 20(1):1. PubMed ID: 29329602
    [Abstract] [Full Text] [Related]

  • 6. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P, Kingsley GH, Scott DL.
    Curr Opin Rheumatol; 2008 May 02; 20(3):251-6. PubMed ID: 18388514
    [Abstract] [Full Text] [Related]

  • 7. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec 02; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 8. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb 02; 19(105):30-4. PubMed ID: 20455343
    [Abstract] [Full Text] [Related]

  • 9. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF.
    N Engl J Med; 1996 May 16; 334(20):1287-91. PubMed ID: 8609945
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A.
    Health Technol Assess; 2016 Apr 16; 20(35):1-610. PubMed ID: 27140438
    [Abstract] [Full Text] [Related]

  • 11. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR.
    Am J Med; 1988 Oct 14; 85(4A):39-44. PubMed ID: 3052055
    [Abstract] [Full Text] [Related]

  • 12. Pharmacoeconomics of long-term treatment of rheumatoid arthritis.
    Blumenauer B, Coyle D, Tugwell P.
    Expert Opin Pharmacother; 2002 Apr 14; 3(4):417-22. PubMed ID: 11934345
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy in rheumatoid arthritis.
    Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA.
    Curr Opin Rheumatol; 2001 May 14; 13(3):177-83. PubMed ID: 11333345
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Newer approaches to the treatment of rheumatoid arthritis.
    Finesilver AG.
    WMJ; 2003 May 14; 102(7):34-7. PubMed ID: 14711022
    [Abstract] [Full Text] [Related]

  • 16. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA, Bingham CO.
    Semin Arthritis Rheum; 2005 Dec 14; 35(3):185-96. PubMed ID: 16325659
    [Abstract] [Full Text] [Related]

  • 17. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
    Kobayashi S, Kanai Y.
    Nihon Rinsho; 2002 Dec 14; 60(12):2351-6. PubMed ID: 12510361
    [Abstract] [Full Text] [Related]

  • 18. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
    Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.
    Clin Exp Rheumatol; 2012 Dec 14; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
    [Abstract] [Full Text] [Related]

  • 19. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.
    Ann Intern Med; 2009 Nov 03; 151(9):612-21. PubMed ID: 19884622
    [Abstract] [Full Text] [Related]

  • 20. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.
    Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN.
    Ann Intern Med; 2008 Jan 15; 148(2):124-34. PubMed ID: 18025440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.